XOMA Royalty Corporation
$40
▼
-0.3%
2026-04-21 10:22:00
www.xoma.com
NGM: XOMA
Explore XOMA Royalty Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$463.38 M
Current Price
$40
52W High / Low
$40.74 / $20.59
Stock P/E
14.61
Book Value
$7.07
Dividend Yield
1.18%
ROCE
4.79%
ROE
34.12%
Face Value
—
EPS
$1.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
0.68
Debt / Equity
126.54
Current Ratio
3.37
Quick Ratio
3.37
Forward P/E
17.17
Price / Sales
8.39
Enterprise Value
$505.75 M
EV / EBITDA
35.23
EV / Revenue
9.7
Rating
None
Target Price
$65.75
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Capital efficiency is modest.
- Leverage is relatively high.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CEL-SCI Corporation | $3.94 | — | $33.32 M | — | -107.75% | -2.12% | $13.48 / $1.98 | $1.38 |
| 2. | Nutriband Inc. | $4.2 | — | $51.13 M | — | -103.12% | -1.36% | $11.68 / $3.42 | $0.62 |
| 3. | Rein Therapeutics Inc. | $1.83 | — | $51.31 M | — | -121.99% | -1.4% | $2.4 / $1.02 | $-1.02 |
| 4. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 5. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 6. | MoonLake Immunotherapeutics | $17.89 | — | $1.32 B | — | -64.61% | -60.78% | $62.75 / $5.95 | $4.27 |
| 7. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.43 M | 0.53 M | 5.38 M | 4.32 M | 2.34 M | — |
| Operating Profit | 2.18 M | -1.33 M | 4.6 M | 5.93 M | -30.25 M | — |
| Net Profit | 6.1 M | 14.05 M | 9.19 M | 2.37 M | -3.97 M | — |
| EPS in Rs | 0.51 | 1.18 | 0.77 | 0.2 | -0.33 | -1.59 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 11.66 M | 10.22 M | 4.76 M | 6.03 M |
| Operating Profit | 11.38 M | -39.98 M | -23.46 M | -17.41 M |
| Net Profit | 31.71 M | -13.82 M | -40.83 M | -17.1 M |
| EPS in Rs | 2.66 | -1.16 | -3.43 | -1.44 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 272.7 M | 221.28 M | 234.3 M | 140.38 M |
| Total Liabilities | 188.76 M | 159.38 M | 145.58 M | 16.37 M |
| Equity | 83.94 M | 61.9 M | 88.72 M | 124.01 M |
| Current Assets | 117.26 M | 125.6 M | 169.31 M | 61.25 M |
| Current Liabilities | 34.82 M | 24.37 M | 19.5 M | 6.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 2.87 M | -13.75 M | -18.16 M | -12.88 M |
| Investing CF | 50.89 M | -28.26 M | -0.71 M | -20.22 M |
| Financing CF | -26.46 M | -11.13 M | 120.59 M | -4.45 M |
| Free CF | -17.85 M | -13.77 M | -18.18 M | -28.13 M |
| Capex | -20.73 M | -0.02 M | -0.02 M | -15.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 114.8% | -21.06% | — | — |
| Earnings Growth % | 66.15% | -138.72% | — | — |
| Profit Margin % | -135.23% | -858.15% | -283.79% | — |
| Operating Margin % | -391.15% | -493.13% | -288.93% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -53.06% | -827.28% | -282.31% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.